ANAB stock forecast, quote, news & analysis
AnaptysBio Inc is a clinical-stage biotechnology company... Show more
Why AnaptysBio (ANAB) Stock Is Down -18.5% in the Last 30 Days
Key Takeaways
- AnaptysBio shares fell approximately 18.5% over the past 30 days, dropping from $67.50 on June 30, 2026, to $55.02 as of July 30, 2026.
- The decline was primarily driven by the disappointing outcome of the July 14–17 Delaware Chancery Court trial against GSK's Tesaro unit, in which AnaptysBio sought reversion of the cancer drug Jemperli.
- The stock has now lost roughly 16% over the broader quarter, reversing gains built on speculation ahead of the high-stakes litigation.
- Despite the selloff, Wall Street analysts maintain a consensus "Strong Buy" rating with an average price target of approximately $87, suggesting the royalty-based business model retains underlying value.
- Upcoming Q2 2026 earnings, expected around August 5, and any post-trial settlement developments remain critical near-term catalysts for the stock.
AnaptysBio (ANAB) Company Overview and Market Position
AnaptysBio, Inc. is a San Diego-based biotechnology company that has undergone a dramatic strategic transformation. In April 2026, the company completed the taxable spin-off of its drug development assets into First Tracks Biotherapeutics, pivoting to an asset-light royalty management business model. The company now primarily collects tiered royalties on net sales of Jemperli (dostarlimab), a fast-growing oncology drug commercialized by GSK through its Tesaro subsidiary. AnaptysBio's royalty rates on Jemperli range from 8% to 25% depending on sales thresholds, with patent protection extending into the mid-2030s. The company also manages financial collaborations for imsidolimab with Vanda Pharmaceuticals. With a market capitalization near $1.63 billion, AnaptysBio operates with minimal overhead, targeting a 95% EBIT margin and holding over $140 million in net cash, while a $100 million share buyback program underscores management's focus on returning value to shareholders.
AnaptysBio (ANAB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AnaptysBio shares declined approximately 18.5%, falling from a closing price of $67.50 on June 30, 2026, to an intraday price of $55.02 on July 30, 2026. The selloff was concentrated in a sharp three-day window from July 14 through July 16, during which the stock lost roughly 22% of its value as the GSK trial unfolded. The stock reached an intra-month low of $50.29 on July 20 before partially recovering.
Looking at the broader quarter, AnaptysBio shares have declined approximately 16% from the $65.73 close on April 30, 2026. The quarterly trend has been shaped by two competing forces: a significant rally in late April following the Delaware court's dismissal of Tesaro's anticipatory breach claim, and the subsequent unwind of those gains after the July trial. The stock's 52-week range spans from $11.40 to $72.36, underscoring the extreme volatility that has characterized this royalty-focused name.
What Drove ANAB Stock Price in the Last 30 Days
The overwhelming driver of AnaptysBio's 30-day decline was the outcome of the Delaware Chancery Court trial held July 14–17, 2026. AnaptysBio had sued GSK's Tesaro unit, alleging material breaches of the 2014 Collaboration and Exclusive License Agreement governing Jemperli. The company sought reversion of the drug's rights—a scenario that some hedge funds, including Laughing Water Capital, had argued could value ANAB shares near $300. When the trial concluded without a decisive victory for AnaptysBio, the stock's speculative premium collapsed, erasing billions in market value over just a few sessions.
Compounding the litigation-driven selloff, AnaptysBio was removed from several Russell indices in late June, including the Russell Microcap Index and Russell 3000E, triggering passive fund rebalancing that added selling pressure. Additionally, short interest stood at 18% of the float as of mid-July, and some insider Form 144 filings in late June and early July may have contributed to cautious sentiment heading into the trial.
What Drove ANAB Stock Performance Over the Last Quarter
The quarterly performance of AnaptysBio reflects a broader narrative of legal optionality meeting reality. The quarter opened with strong momentum following the April 24, 2026, Delaware Chancery Court ruling that dismissed Tesaro's anticipatory breach claim and preserved AnaptysBio's contracted royalty rates. That decision sent shares surging from the mid-$30s in early April to above $66 by late April, as investors priced in a higher probability of a favorable July trial outcome.
Between May and late June, the stock consolidated in a range between roughly $50 and $70, supported by the royalty-backstopped valuation floor and the $100 million buyback authorization. However, the Q1 2026 earnings miss in mid-May—where AnaptysBio reported an EPS of -$1.84 versus a consensus estimate of -$0.62—reminded investors of ongoing operating expenses and the transition costs associated with the First Tracks spin-off. The July trial then served as the quarter's decisive event, breaking the trading range to the downside and resetting the stock's risk premium.
Trending AI Robots
For traders seeking data-driven strategies in volatile markets like biotechnology, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of algorithmic trading bots that trade thousands of tickers across equities, ETFs, and cryptocurrencies, but only the top-performing and most relevant bots appear in this curated section. Each bot employs distinct strategies—from swing trading and trend following to pattern recognition and mean reversion—spanning different timeframes and performance metrics. The Trending AI Robots section enables traders to browse real-time bot performance, track historical win rates, and identify strategies aligned with current market conditions. Exploring this page can help investors discover automated approaches tailored to their trading style.
ANAB Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors will shape AnaptysBio's trajectory. The most immediate catalyst is the company's Q2 2026 earnings report, estimated for August 5, 2026, which should provide clarity on Jemperli royalty revenue, operating expense trends following the First Tracks spin-off, and progress on the $100 million buyback. The 11 analysts covering the stock maintain a consensus "Strong Buy" rating with price targets ranging from $70 to $140, reflecting an expectation that the underlying royalty stream holds significant standalone value even without a favorable litigation outcome.
Investors should also monitor any post-trial settlement discussions or appeal filings between AnaptysBio and GSK, as well as Jemperli sales growth and potential label expansions that could boost royalty income. The company's $140 million net cash position provides a financial buffer, but the resolution of the Sagard royalty obligation by mid-2027 remains an important milestone. Broader biotech sector sentiment, interest rate expectations, and M&A activity in the royalty-pharma space may also influence ANAB's valuation multiple in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for ANAB shows an upward move is likely
ANAB's Aroon Indicator triggered a bullish signal on July 17, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 245 similar instances where the Aroon Indicator showed a similar pattern. In of the 245 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where ANAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .
ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for ANAB moved out of overbought territory on July 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANAB as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ANAB turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .
ANAB moved below its 50-day moving average on July 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ANAB crossed bearishly below the 50-day moving average on July 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (123.457) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (6.489) is also within normal values, averaging (420.906).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of therapeutic antibodies for inflammation and immuno-oncology
Industry Biotechnology